Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Mol Cell Biochem ; 367(1-2): 51-8, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22661379

ABSTRACT

Regulation and downstream effects of mitochondrial protein S-glutathionylation in response to oxidative stress are poorly understood. The study aim was to determine whether anti-oxidants such as catalase and estradiol alter mitochondrial protein S-glutathionylation and in turn affect apoptosis following ultraviolet B (UV-B) light irradiation. HeLa cells were transduced with increasing amounts of adenovirus encoding catalase (Ad-Cat) and ß-galactosidase (Ad-Lac Z) or pre-incubated with estradiol before induction of apoptosis by UV-B light exposure. Inhibition of mitochondrial protein S-glutathionylation was assessed using autoantibodies specific for the non-S-glutathionylated form of PDC-E2. The percentage of apoptotic cells following UV-B irradiation were not significantly different between mock cells (cells with no virus infection) and Ad-Cat and Ad-Lac Z infected cells at all viral doses (all p > 0.050). Autoantibody staining of non-S-glutathionylated PDC-E2 in apoptotic cells was three times greater in only Ad-Cat infected cells compared to only Ad-Lac Z infected cells (81.3 ± 16.7 vs 26 ± 7.2 %, respectively, p = 0.030). Similarly estradiol treatment (33 and 100 nM) also significantly increased PDC-E2 staining in apoptotic cells compared to non-treated cells (both p < 0.010). The percentage of apoptotic cells was not significantly different with any of the estradiol concentrations (all p > 0.100). The observed procaspase 12 cleavage following UV-B irradiation suggests that a mitochondrial-independent apoptotic pathway was activated. In conclusion, following an apoptotic stimulus, estradiol may inhibit mitochondrial protein S-glutathionylation without inhibiting apoptosis. This effect may play a role in ninefold greater prevalence of autoantibodies against PDC-E2 in women with primary biliary cirrhosis.


Subject(s)
Antioxidants/physiology , Catalase/physiology , Estradiol/physiology , Glutathione/metabolism , Mitochondrial Proteins/metabolism , Antioxidants/pharmacology , Apoptosis , Catalase/metabolism , Dihydrolipoyllysine-Residue Acetyltransferase/metabolism , Estradiol/pharmacology , Humans , Oxidative Stress
2.
J Immunotoxicol ; 8(4): 258-64, 2011.
Article in English | MEDLINE | ID: mdl-21718087

ABSTRACT

Maternal environmental exposures during pregnancy are known to affect disease onset in adult offspring. For example, maternal asthma exacerbations during pregnancy can worsen adult asthma in the offspring. Cigarette smoking during pregnancy is associated with future onset of cardiovascular disease, obesity and diabetes. However, little is known about the effect of maternal environmental exposures on offspring susceptibility to liver disease. This pilot study examined the long-term effect of maternal allergen challenge and/or cigarette smoking during pregnancy on hepatic inflammation and fibrosis in adult mouse offspring. Ovalbumin (OVA) or phosphate-buffered saline (PBS)-sensitized/challenged CD-1 dams were exposed to mainstream cigarette smoke (MCS) or filtered air from gestational day 4 until parturition. Eight weeks postnatally, offspring were sacrificed for comparison of hepatic histology and mRNA expression. Adult male offspring of OVA-sensitized/challenged dams exposed to MCS (OSM) displayed significantly increased liver fibrosis (9.2% collagen content vs. <4% for all other treatment groups). These mice also had 1.8-fold greater collagen 1A1 mRNA levels. From the results here, we concluded that maternal allergen challenge in combination with cigarette smoke exposure during pregnancy may be an important risk factor for liver disease in adult male offspring.


Subject(s)
Allergens/adverse effects , Liver Cirrhosis/chemically induced , Maternal Exposure/adverse effects , Prenatal Exposure Delayed Effects/chemically induced , Smoke/adverse effects , Tobacco Smoke Pollution/adverse effects , Animals , Animals, Outbred Strains , Collagen Type I/genetics , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Drug Synergism , Female , Gene Expression Regulation, Developmental/drug effects , Inhalation Exposure , Litter Size/drug effects , Liver/drug effects , Liver/pathology , Liver Cirrhosis/pathology , Male , Mice , Ovalbumin/administration & dosage , Pregnancy , RNA, Messenger/metabolism , Receptor, Platelet-Derived Growth Factor beta/genetics , Receptor, Platelet-Derived Growth Factor beta/metabolism , Sex Ratio
3.
Inhal Toxicol ; 22 Suppl 2: 100-6, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21142798

ABSTRACT

BACKGROUND: The use of nanoparticles (NPs) in technological applications is rapidly expanding, but the potential health effects associated with NP exposure are still largely unknown. Given epidemiological evidence indicating an association between inhaled ambient ultrafine particles and increased risk of cardiovascular disease morbidity and mortality, it has been suggested that exposure to NPs via inhalation may induce similar cardiovascular responses. METHODS: Male C57BL/6 mice were exposed via whole-body inhalation to either filtered air (FA) or nickel hydroxide (NH) NPs (100, 150, or 900 µg/m(3)) for 1, 3, or 5 consecutive days (5 h/day). At 24-h post-exposure, vascular function in response to a vasoconstrictor, phenylephrine (PE), and a vasodilator, acetylcholine (ACh), was measured in the carotid artery. RESULTS: Carotid arteries from mice exposed to all concentrations of NH-NPs showed statistically significant differences in graded doses of PE-induced contractile responses compared with those from FA mice. Similarly, vessels from NH-NP-exposed mice also demonstrated impaired vasorelaxation following graded doses of ACh as compared with FA mice. CONCLUSIONS: These results suggest that short-term exposure to NH-NPs can induce acute endothelial disruption and alter vasoconstriction and vasorelaxation. These findings are consistent with other studies assessing vascular tone and function in the aorta, coronary, and mesenteric vessels from mice exposed to motor vehicular exhaust and concentrated ambient particles.


Subject(s)
Air Pollutants/toxicity , Inhalation Exposure/adverse effects , Nanoparticles/toxicity , Nickel/toxicity , Vasoconstriction/drug effects , Vasodilation/drug effects , Acetylcholine/analysis , Animals , Aorta/physiopathology , Carotid Arteries/physiopathology , Male , Mice , Mice, Inbred C57BL , Muscle, Smooth, Vascular/blood supply , Particle Size , Vasodilator Agents/analysis
4.
J Immunotoxicol ; 6(4): 266-75, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19908945

ABSTRACT

Owing to increased obesity, non-alcoholic fatty liver disease (NAFLD) is now the most prevalent liver disease in the United States. NAFLD is considered a component of metabolic syndrome, a cluster of disorders that also includes diabetes mellitus, dyslipidemia, arteriosclerosis, and hypertension. Exposure to ambient air particulate matter with aerodynamic diameters < 2.5 microm (PM(2.5)) is a risk factor for arteriosclerosis and lung disease, but its effect on NAFLD is unknown. PM(2.5) induces pulmonary dysfunction via Toll-like receptor (TLR) activation on alveolar macrophages. TLR activation of Kupffer cells, resident hepatic macrophages, and subsequent pro-inflammatory cytokine production have been shown to play a key role in NAFLD progression. We hypothesized that PM(2.5) exposure is a significant risk factor for the progression of NAFLD. Thus, following exposure of male C57BL/6 mice fed high fat chow (HFC) to concentrated air particulate matter (CAPs) or filtered air for 6 weeks, progression of NAFLD was evaluated by standardized histological assessment of hepatic inflammation and fibrosis. In mice fed HFC, the hepatic inflammatory grade (3.00 +/- 0.00 vs. 1.50 +/- 0.71, P < 0.001) and fibrosis stage (1.00 +/- 0.00 vs. 0.60 +/- 0.52, P = 0.023) were both significantly higher in mice exposed to CAPs versus filtered air, respectively. Increased numbers of Kupffer cells contained PM in CAPs-exposed mice scores of (2.00 +/- 0.94 vs. 0.20 +/- 0.42, respectively, P < 0.001). PM exposure increased IL-6 secretion up to seven-fold in a dose-dependent manner by isolated wild-type but not TLR4(-/-) Kupffer cells (P < 0.050). In conclusion, ambient PM(2.5) exposure may be a significant risk factor for NAFLD progression.


Subject(s)
Air Pollutants/toxicity , Fatty Liver/chemically induced , Kupffer Cells/drug effects , Liver/drug effects , Particulate Matter/toxicity , Animals , Cell Proliferation/drug effects , Cells, Cultured , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Fatty Liver/pathology , Fibrosis/chemically induced , Fibrosis/pathology , Inhalation Exposure , Kupffer Cells/pathology , Liver/pathology , Macrophage Activation , Male , Mice , Mice, Inbred C57BL
5.
Dig Dis Sci ; 53(7): 1988-93, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18392679

ABSTRACT

Statin treatment reduces hypercholesterolemia and may be anti-inflammatory. Case reports noted decreased alkaline phosphatase and histological improvement following statin treatment in primary biliary cirrhosis. The objective of this study was to assess the long-term effects of statin treatment in primary biliary cirrhosis. A retrospective analysis compared clinical and biochemical data from 15 hypercholesterolemic individuals with primary biliary cirrhosis who were treated long-term with atorvastatin with an age and gender matched, primary biliary cirrhosis control group. A significant decrease in total cholesterol and low-density lipoprotein (LDL)-cholesterol (p < or = 0.002) was observed throughout atorvastatin treatment (median time 2.5 years). LDL-cholesterol levels in the control group were not significantly changed after 2 years (p > 0.050). No significant changes were noted in alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin and Mayo Risk Score in either group (p > 0.05). Long-term atorvastatin treatment reduced LDL-cholesterol in primary biliary cirrhosis, but there was no evidence of any anti-inflammatory effect.


Subject(s)
Anticholesteremic Agents/therapeutic use , Heptanoic Acids/therapeutic use , Hypercholesterolemia/drug therapy , Liver Cirrhosis, Biliary/drug therapy , Pyrroles/therapeutic use , Aged , Atorvastatin , Female , Humans , Hypercholesterolemia/complications , Lipids/blood , Liver Cirrhosis, Biliary/complications , Liver Function Tests , Male , Middle Aged , Quality of Life , Retrospective Studies , Treatment Outcome
6.
J Autoimmun ; 30(4): 238-45, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18023559

ABSTRACT

Primary biliary cirrhosis is characterized by chronic hepatic inflammation and immune mediated apoptosis of bile duct epithelial cells. Delayed macrophage phagocytosis of opsonized apoptotic cells, noted in other autoimmune diseases, may promote inflammation. Recent studies suggest serum anti-CD16 autoantibodies contribute to impaired macrophage phagocytosis by blocking complement receptor 3 (CR3) signaling via CD16. Therefore, serum anti-CD16 levels and the ability of monocyte derived macrophages from individuals with PBC to phagocytosis apoptotic cells were compared to controls. The mean level of anti-CD16 IgM autoantibodies (0.86+/-0.62 v. 0.35+/-0.22, respectively, p=0.031) was increased in PBC compared to control sera, and mean PBC phagocytosis of opsonized apoptotic cells was significantly decreased compared to controls (23.9+/-12.2% v. 43.9+/-14.4%, respectively, p=0.020). However, PBC phagocytosis of opsonized apoptotic cells was not significantly affected by the presence or absence of autologous serum (20.8+/-13.5% v. 23.9+/-12.2%, respectively, p=0.560). PBC phagocytosis of opsonized apoptotic cells inversely correlated with CD16 (and CR3) expression levels on Day 5 after culture in the presence or absence of autologous serum (r=-0.546, p=0.033 and r=-0.519, p=0.042, respectively). Phagocytosis of non-opsonized apoptotic cells did not correlate with CD16 or CR3 expression (p>0.050). In conclusion, PBC macrophage phagocytosis of opsonized apoptotic cells is impaired, irrespective of serum factors and may increase hepatic inflammation.


Subject(s)
Apoptosis/immunology , Autoantibodies/blood , Liver Cirrhosis, Biliary/immunology , Phagocytosis/immunology , Receptors, IgG/immunology , Autoantigens/immunology , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Humans , Liver Cirrhosis, Biliary/blood , Liver Cirrhosis, Biliary/pathology , Macrophages/immunology , Male , Middle Aged , Opsonin Proteins/immunology
7.
J Autoimmun ; 27(4): 232-41, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17222534

ABSTRACT

Primary biliary cirrhosis (PBC) is characterized by loss of tolerance against ubiquitously expressed mitochondrial autoantigens followed by biliary and salivary gland epithelial cell (BEC and SGEC) destruction by autoreactive T cells. It is unclear why BECs and SGECs are targeted. Previous work demonstrated that the reduced form of the major PBC autoantigen predominated in apoptotic BECs and SGECs as opposed to an oxidized form in other apoptotic cells. This led to the hypothesis that presentation of novel self-peptides from phagocytosed apoptotic BECs might contribute to BEC targeting by autoreactive T cells. The effect of autoantigen redox status on self-peptide formation was examined along with the phagocytic ability of BECs. Oxidation of PBC autoantigens first was shown to be due to protein S-glutathionylation of lipoyllysine residues. Absence of protein S-glutathionylation generated novel self-peptides and affected T cell recognition of a lipoyllysine containing peptide. Liver biopsy staining revealed BEC phagocytosis of apoptotic BECs (3.74+/-2.90% of BEC) was present in PBC (7 of 7 cases) but not in normal livers (0 of 3). BECs have the ability to present novel mitochondrial self-peptides derived from phagocytosed apoptotic BECs. Apoptotic cell phagocytosis by non-professional phagocytes may influence the tissue specificity of autoimmune diseases.


Subject(s)
Apoptosis/immunology , Liver Cirrhosis, Biliary/immunology , Phagocytosis/immunology , T-Lymphocytes/immunology , Animals , Apoptosis/genetics , Autoantigens/immunology , Autoantigens/metabolism , Cathepsin B/metabolism , Dihydrolipoyllysine-Residue Acetyltransferase/metabolism , Epithelial Cells/immunology , Epithelial Cells/pathology , Female , Glutathione/metabolism , HeLa Cells , Humans , Liver Cirrhosis, Biliary/metabolism , Liver Cirrhosis, Biliary/pathology , Lysine/analogs & derivatives , Lysine/chemistry , Mice , Oxidation-Reduction , Peptide Hydrolases/metabolism , Rats , Thioctic Acid/analogs & derivatives , Thioctic Acid/chemistry
9.
Cancer Res ; 64(11): 3885-91, 2004 Jun 01.
Article in English | MEDLINE | ID: mdl-15172998

ABSTRACT

Kruppel-like factor 6 (KLF6) is a tumor suppressor gene inactivated in prostate and colon cancers, as well as in astrocytic gliomas. Here, we establish that KLF6 mediates growth inhibition through an interaction with cyclin D1, leading to reduced phosphorylation of the retinoblastoma protein (Rb) at Ser(795). Furthermore, introduction of KLF6 disrupts cyclin D1-cyclin-dependent kinase (cdk) 4 complexes and forces the redistribution of p21(Cip/Kip) onto cdk2, which promotes G(1) cell cycle arrest. Our data suggest that KLF6 converges with the Rb pathway to inhibit cyclin D1/cdk4 activity, resulting in growth suppression.


Subject(s)
Cyclin D1/metabolism , Cyclin-Dependent Kinases/antagonists & inhibitors , Proto-Oncogene Proteins , Trans-Activators/metabolism , CDC2-CDC28 Kinases/metabolism , Cell Division/genetics , Cyclin D1/antagonists & inhibitors , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinases/metabolism , Cyclins/biosynthesis , Cyclins/metabolism , Gene Silencing , HCT116 Cells , Humans , Kruppel-Like Factor 6 , Kruppel-Like Transcription Factors , RNA, Small Interfering/genetics , Trans-Activators/antagonists & inhibitors , Trans-Activators/genetics , Transfection
10.
Dev Immunol ; 9(2): 103-11, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12739787

ABSTRACT

Primary biliary cirrhosis (PBC) is an autoimmune disease characterized by intrahepatic bile duct destruction and the production of anti-mitochondrial antibodies (AMA). The absence of an animal model has been a striking impedance in defining the molecular basis of disease. Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis. We hypothesized that this pathology would be augmented if immunization occurred in the presence of IFN-gamma injections. Accordingly, SJL/J mice were immunized with PDC-E2 and, for purpose of control, alpha-casein. Subgroups of mice were also treated with exogenous IFN-gamma. As expected, mice immunized with PDC-E2, with or without IFN-gamma, developed high titer AMAs. In contrast, mice immunized with alpha-casein, develop antinuclear antibodies. More importantly, the livers from mice immunized with PDC-E2 and/or those immunized with alpha-casein all displayed lymphoid cell infiltration to the portal tracts, irrespective of bile duct size. Indeed, there was no significant difference between the experimental and the control groups by histologic analysis. Thus, autoimmune cholangitis in these mice is antigen non-specific.


Subject(s)
Autoimmune Diseases/etiology , Cholangitis/etiology , Adjuvants, Immunologic/administration & dosage , Animals , Autoantibodies/biosynthesis , Autoantigens/administration & dosage , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Bile Ducts, Intrahepatic/pathology , Cholangitis/immunology , Cholangitis/pathology , Chronic Disease , Disease Models, Animal , Freund's Adjuvant/administration & dosage , Immunization , Interferon-gamma/administration & dosage , Liver Cirrhosis, Biliary/etiology , Liver Cirrhosis, Biliary/immunology , Liver Cirrhosis, Biliary/pathology , Mice , Mitochondria/enzymology , Mitochondria/immunology , Pyruvate Dehydrogenase Complex/administration & dosage , Pyruvate Dehydrogenase Complex/immunology , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...